Peripheral Neuropathies in Human Immunodeficiency Virus Infection

Höke, Ahmet; Cornblath, David R.

doi:10.1016/b978-0-7216-9491-7.50097-1

Cited by 18 publications

(13 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Cherry et al (2002) reported that DDX drug use correlated with reduction in mitochondrial DNA content in subcutaneous fat tissue in HIV patients, but there was no correlation with development of neuropathy in these patients. This observation further supports the hypothesis that DDX neurotoxicity may not be directly related to the ability of DDX drugs inhibiting the mitochondrial DNA polymerase-␥ (for review, see Höke and Cornblath, 2005).…”

Section: Discussionsupporting

confidence: 73%

“…Human immunodeficiency virus (HIV)-associated sensory neuropathy (SN) is the most common neurological complication of HIV infection, symptomatically affecting over one third of patients with HIV (for review, see Keswani et al, 2002;Höke and Cornblath, 2005). The symptoms of HIV-SN are dominated by neuropathic pain, which is often excruciating.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Establishment of a Rodent Model of HIV-Associated Sensory Neuropathy

Keswani¹,

Jack²,

Zhou³

et al. 2006

J. Neurosci.

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-associated sensory neuropathy (SN)is the most common neurological complication of HIV infection in the current highly active antiretroviral therapy era. The painful sensory neuropathy is associated with the use of dideoxynucleoside antiretrovirals, and its development limits the choice of antiretroviral drugs in affected patients. There are presently no effective therapies for HIV-SN, and moreover there has been no robust animal model of HIV-SN in which candidate therapeutic agents can be tested. In this paper, we show that we have established a rodent model of HIV-SN by oral administration of a dideoxynucleoside drug, didanosine, to transgenic mice expressing the HIV coat protein gp120 under a GFAP promoter. The neuropathy in these rodents is characterized by distal degeneration of unmyelinated sensory axons, similar to the "dying back" pattern of C-fiber loss seen in patients with HIV-SN. This model will be useful in examining mechanisms of distal axonal degeneration and testing potential neuroprotective compounds that may prevent development of the sensory neuropathy.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Establishment of a Rodent Model of HIV-Associated Sensory Neuropathy

Keswani¹,

Jack²,

Zhou³

et al. 2006

J. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Human immunodeficiency virus (HIV) infection and associated treatments can cause many different types of peripheral neuropathies, depending on the stage of infection and antiretroviral drugs used (for more detail see Hoke and Cornblath [100]). The most common neurological complication of HIV infection that affects the peripheral nervous system is a sensory predominant distal symmetric polyneuropathy [101].…”

Section: Human Immunodeficiency Virus-associated Sensory Neuropathymentioning

confidence: 99%

Animal Models of Peripheral Neuropathies

Höke

2012

Neurotherapeutics

Self Cite

View full text Add to dashboard Cite

Peripheral neuropathies are common neurological diseases, and various animal models have been developed to study disease pathogenesis and test potential therapeutic drugs. Three commonly studied disease models with huge public health impact are diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and human immunodeficiency virus-associated sensory neuropathies. A common theme in these animal models is the comprehensive use of pathological, electrophysiological, and behavioral outcome measures that mimic the human disease.

show abstract

“…In recent years, a spectrum of metabolic and morphologic alterations has emerged among HIV-infected patients receiving HAART. Additionally, neurological syndromes, such as antiretroviral toxic neuropathy, have been clinically well characterized 7,8 . The HANWS is a unique toxic syndrome, more recently reported, and to date incompletely characterized 4 .…”

Section: Discussionmentioning

confidence: 99%

HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases

Vidal

Clifford²,

Ferreira

et al. 2007

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-We describe two Brazilian patients with HIV-associated neuromuscular weakness syndrome (HANWS), a unique clinical toxic syndrome that was recently reported in developed countries. Both patients were women, used stavudine and had hyperlactatemia, one of them with lactic acidosis. Eletrophysiological studies were consistent with axonal neuropathy. After discontinuation of antiretroviral therapy the patients had significant improvement in neurologic manifestations, and normalization of lactate levels. To our knowledge, this is the first report of HANWS in developing countries. Growing use of antiretroviral therapy in this setting, particularly stavudine, make it likely that similar cases will be observed.KEy WoRdS: neuromuscular diseases, peripheral neuropathies, antiretroviral agents, human immunodeficiency virus.Síndrome da fraqueza neuromuscular associada ao HIV no Brasil: relato dos dois primeiros casos RESUMo -os autores descrevem dois pacientes brasileiros com a síndrome da fraqueza neuromuscular associada ao HIV, uma síndrome tóxica, clínicamente particular, que foi recentemente relatada em paí-ses desenvolvidos. Ambas pacientes eram do sexo feminino, usavam estavudina e apresentaram hiperlactatemia, uma delas com acidose láctica. os exames electrofisiológicos foram consistentes com neuropatia axonal. As pacientes melhoraram significativamente das alterações neurológicas, assim como normalizaram os níveis de lactato, após descontinuar o uso dos antiretrovirais. Até onde sabemos, este é o primeiro relato da síndrome de fraqueza neuromuscular associada ao HIV em países em desenvolvimento. Nesse contexto, o uso crescente de antiretrovirais, particularmente a estavudina, possibilitarão que casos similares sejam observados.PAlAVRAS-CHAVE: doenças neuromusculares, neuropatia periférica, terapia antiretroviral, vírus da imunodeficiência humana.

show abstract

Peripheral Neuropathies in Human Immunodeficiency Virus Infection

Cited by 18 publications

References 151 publications

Establishment of a Rodent Model of HIV-Associated Sensory Neuropathy

Establishment of a Rodent Model of HIV-Associated Sensory Neuropathy

Animal Models of Peripheral Neuropathies

HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases

Contact Info

Product

Resources

About